Board of Advisors
Donald R. Reynolds
Don practices in the areas of capital markets, securities law, mergers & acquisitions, venture capital and corporate law. He joined the firm in 1993, prior to which he practiced at Wilson, Sonsini, Goodrich & Rosati, the largest law firm in Silicon Valley. Don’s experience ranges from representing start-up companies in their initial organizations and financings to representing companies and underwriters in public offerings, mergers & acquisitions, and SEC reporting and compliance matters. Don has worked on over 75 public offerings, raising over $6 billion in aggregate.
Don teaches Securities Regulation at Campbell University’s law school and guest lectures on corporate governance at UNC-Chapel Hill’s Kenan-Flagler Business School. He chaired the NCBA Securities Regulation Committee from 1997 through 2001 and was on the NCBA Business Council from 2000 through 2003. Don is the only Securities & Corporate Finance attorney outside Charlotte to have been listed in North Carolina Super Lawyers each year since 2007. Don received his B.A. from Whitman College and his J.D. from New York University School of Law.
Eric serves as the chief operating officer of Diplomat Specialty Infusion Group. In his role, Eric oversees the day-to-day operations and leads efforts in strategic planning. Eric previously served as the chief operating officer of BioRx, a position he held since the company’s founding in 2004. Before co-founding BioRx in 2004, Eric Hill accumulated over 20 years of sales, general management and executive management experience in the specialty pharmacy and infusion industry.
Eric has served as the vice president of Blood Products for Coram Healthcare, a $500 million public specialty infusion company based in Denver, Colo. In this role, Eric had executive management responsibility for sales and operations related to blood products, including hemophilia clotting factors, intravenous immunoglobulin (IVIG) and other related biological agents. While at Coram, Eric held other assignments including vice president of sales and marketing for a managed care subsidiary and regional vice president. Before joining Coram Healthcare in 1995, Eric worked for more than five years with National Medical Care as a field sales representative, a regional sales manager and also as a product manager.
Eric graduated from Wake Forest University with a bachelor’s degree in psychology in 1988.
Phil serves as president of Diplomat Specialty Infusion Group. Prior to this role, Phil served as president of BioRx, a position he held since the company’s founding in 2004. Prior to co-founding BioRx, Phil co-founded CliniCare, a respiratory equipment provider for over a thousand nursing home beds. After selling his equity share in the company to his partner, Phil co-founded and financed PRO2, a nine-branch business serving the respiratory therapy market. He served as a manager for PRO2 until 2010.
Phil entered the medical field in 1992 when he got his start with Apria, eventually rising to the position of senior account executive. In this role, he more than tripled the sales in his region over a five-year period. Phil then entered the specialty pharmaceutical field with Alpha Therapeutics. After nearly five years of success, he was recruited by Coram for the position of area market director for its blood products division, with responsibilities for an 11-state region, where he managed 23 sales and marketing representatives.
Phil earned his Bachelor of Arts degree in Communications and Marketing from Spring Hill College.
Simon has a long career in drug development including recent leadership roles as President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Vice President of Oncology Pharma Business at Hoffman-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise at Hoffman-LaRoche; and Vice President and Head of Drug Development in Shearwater Corporation. Formerly, he was a faculty in the Department of Pharmacology in College of Medicine in the University of Saskatchewan, where he obtained his PhD in Pharmacology. During his longstanding career in pharmaceutical development, Simon has previously led the late stage development and commercial launch of multiple proprietary pharmaceutical products.
In addition to his PhD in Pharmacology, Simon obtained a Master of Science in Toxicology from Concordia University, a Bachelor of Science in Environmental Studies from the University of Waterloo, and completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.
Cornelius P. “Neal” McCarthy
Cornelius P. “Neal” McCarthy is a founding partner and managing director of Fairmount Partners, a leading investment bank. Mr. McCarthy focuses primarily on healthcare and pharmaceutical outsourced services. He has assisted over 200 clients complete public offerings, leveraged buyouts, and private placements. He has represented over 110 pharmaceutical services clients complete financings, acquisitions and mergers throughout North and South America, Europe, Asia and Australia.
Prior to founding the Company, Mr. McCarthy was the US Head of Corporate Finance and Head of Healthcare Investment Banking at Investec, Inc., an international banking group based in the UK. Before joining Investec, Mr. McCarthy served in Los Angeles for three years as Managing Director of Laidlaw & Company, and five years as a Vice President with Kemper Securities/Bateman Eichler, Hill Richards, where he specialized in mergers and acquisitions. Mr. McCarthy also was Vice President of Woolcott & Company, a private investment bank based in New York, and practiced securities and general corporate law for the firm of Gibbons, Del Deo, Dolan et al.
He previously served on the Board of Phoenix International Life Sciences Inc., and represented that company in acquisitions which built one of the five largest CROs in the world. He subsequent joined Medpace as a member of the Board of Directors in 2003 and served until the sale of the business in 2014, helping build one of the world’s largest CROs. He is a member of the Drug Information Association and the American Association of Pharmaceutical Scientists.
Mr. McCarthy received his legal degree from Villanova University School of Law and earned his undergraduate degree from the University of Virginia, where he was an Echols Scholar.